Wegovy 1.7mg side effects: separating the likely from the serious

The misconception: a higher dose means a completely different set of risks

One of the questions our prescribers hear most weeks is whether moving to 1.7mg represents a step-change in how dangerous Wegovy becomes. It doesn't. The side-effect profile at 1.7mg is the same in character as the earlier doses, semaglutide's mechanism, slowing gastric emptying and reducing appetite via the GLP-1 receptor, doesn't change as the dose rises. What changes, modestly, is intensity. Effects that were mild at 1mg may feel a little stronger at 1.7mg, particularly in the first two to three weeks after increasing. That's expected and, for most people, temporary.

According to the NHS patient information for semaglutide, common reactions include nausea, vomiting, diarrhoea, constipation, indigestion, reflux and burping. Fatigue, headache and dizziness are also reported. None of these are unique to 1.7mg (they run through the entire dose ladder) but the 1.7mg step is often where people notice them most clearly, simply because it sits just below the maintenance ceiling. You can read about the side-effect pattern that precedes this point on the 1mg side effects page.

The practical upshot: do not assume any symptom at 1.7mg is automatically more worrying than the same symptom was at a lower dose. Assess by severity, not by number on the pen.

Side effects of Wegovy 1.7mg that are common and usually manageable

Nausea tops the list, it's the side effect most likely to make someone pause. It tends to peak in the day or two after each weekly injection and fade before the next dose. Eating smaller portions, avoiding heavy or fatty meals around injection day, and staying well hydrated all help. Vomiting is less common but does occur, particularly if someone eats a larger meal than their appetite now comfortably accommodates.

Constipation and diarrhoea can alternate or appear independently. Both reflect semaglutide slowing gut transit and altering fluid absorption. Loose stools are more common earlier; constipation becomes more prominent as the dose stabilises. Abdominal discomfort, bloating and reflux complete the main gastrointestinal picture. Fatigue and mild headaches are frequently reported during the titration phase but are rarely severe.

Injection-site reactions (redness, itching or a small lump under the skin) are generally transient and manageable by rotating the injection site between the abdomen, thigh and upper arm. The Wegovy dosing overview covers the titration schedule that leads to this dose, which is useful context for understanding why the sequence is structured the way it is.

The semaglutide side-effects data is drawn from large phase-3 clinical trials including the STEP programme, the STEP 1 trial published in the New England Journal of Medicine enrolled over 1,900 adults and documented the GI-led side-effect profile in detail across the full dose titration.

When to get medical help: side effects that need prompt attention

Most side effects of Wegovy 1.7mg pass without any intervention beyond comfort measures. A few do not. Seek urgent medical attention if you develop severe, persistent abdominal pain that spreads to your back, with or without vomiting. This pattern can indicate acute pancreatitis. Following reports linking GLP-1 medicines to this condition, the MHRA issued a Drug Safety Update in January 2026 reminding patients and clinicians that acute pancreatitis, while uncommon, is a recognised risk that warrants immediate assessment rather than home management.

Other symptoms that require prompt contact with a healthcare professional include: signs of a severe allergic reaction (swelling of the face, throat or tongue; difficulty breathing; rapid heartbeat); significant dehydration from persistent vomiting or diarrhoea; and any new or worsening low mood or thoughts of self-harm. Gallbladder problems (including gallstones) are also more frequent in people losing weight rapidly, so right-sided upper abdominal pain is worth reporting to a clinician promptly rather than waiting.

If you are unsure whether a symptom is serious, contact your prescriber, your GP, or NHS 111. Do not adjust your dose yourself. The side effects at the 2.4mg maintenance dose follow a similar pattern and are worth reading ahead of your next titration step.

Suspected side effects can also be reported directly to the MHRA through the Yellow Card scheme, this applies to patients as well as clinicians and helps the regulator monitor real-world safety signals.

How nume handles 1.7mg prescriptions and clinical review

Wegovy is a prescription-only medicine. At nume, a GPhC-registered Independent Prescriber reads every consultation (a real clinician, not automated software) and side effects are part of what they review before any prescription or dose change is approved. Transfer patients and those requesting a dose increase are asked to provide evidence of their current treatment and response before the prescriber makes a decision.

If side effects have made 1.7mg difficult to tolerate, that is exactly the kind of information our prescribers need. Staying at a previous dose for longer is a legitimate clinical decision, and if you want to understand what to expect when stepping back, you can review the side effects of Wegovy 0.5mg or, for those earlier in the titration, the side effects of Wegovy 0.25mg for comparison. Moving forward to the maximum dose is not compulsory or automatic. Dose management is individual, and the prescriber's job is to make that call safely. If you'd like to discuss your suitability and talk through side effects before starting or continuing treatment, you can check your eligibility through a free consultation with our clinical team.